XML 49 R36.htm IDEA: XBRL DOCUMENT v3.5.0.2
BUSINESS COMBINATION (Details) - USD ($)
$ in Thousands
6 Months Ended 12 Months Ended
Jun. 16, 2016
Mar. 31, 2015
Jan. 12, 2015
Jun. 30, 2016
Jun. 30, 2015
Dec. 31, 2015
Business Acquisition [Line Items]            
Acquisition-related contingent consideration       $ 72,300   $ 45,267
Liquid Ursodeoxycholic Acid (L-UDCA) [Member]            
Business Acquisition [Line Items]            
Intangible assets acquired $ 25,500          
Discount rate percentage 12.00%          
Liquid Ursodeoxycholic Acid (L-UDCA) [Member] | Product rights            
Business Acquisition [Line Items]            
Assets useful life (in years) 17 years          
Asklepion Pharmaceuticals, LLC            
Business Acquisition [Line Items]            
Cash payment   $ 28,400   $ 644 $ 0  
Common stock shares issued (in shares)   661,279        
Value of common stock   $ 15,844        
Acquisition-related contingent consideration   39,100        
Fair value of Pediatric Priority Review Voucher   96,250        
Intangible assets acquired   83,200        
Discount rate percentage           19.00%
Contingent consideration agreement, high amount           $ 16,300
Net present value of service fees           2,900
Total payments of service fees           $ 4,000
Deferred tax liability   39,880        
Assets acquired in business combination   $ 88,500        
Utilized tax rate percentage   45.40%        
Purchase price allocation   $ 91,284        
Asklepion Pharmaceuticals, LLC | Definitive agreement            
Business Acquisition [Line Items]            
Upfront payment     $ 5,000      
Asklepion Pharmaceuticals, LLC | Purchase agreement            
Business Acquisition [Line Items]            
Value of common stock   $ 9,000        
Asklepion Pharmaceuticals, LLC | Product rights            
Business Acquisition [Line Items]            
Assets useful life (in years)   10 years        
Asklepion Pharmaceuticals, LLC | Product rights | United States            
Business Acquisition [Line Items]            
Intangible assets acquired   $ 75,900        
Asklepion Pharmaceuticals, LLC | Product rights | International            
Business Acquisition [Line Items]            
Intangible assets acquired   $ 7,300